Glaucoma Therapeutics Market Share - Latest Market Reports

The glaucoma therapeutics market revenue will likely total US$ 6.6 Bn for 2021, according to Fact.MR. Overall, the market is expected to reach US$ 10 Bn by 2031, expanding 1.5x across the forthcoming decade. Demand for beta-blockers drug class will accelerate, anticipated to register a CAGR of 4.7% from 2021-2031.

This Report also provides the market survey of Glaucoma Therapeutics gives estimations of the Size of Glaucoma Therapeutics Market and the overall Glaucoma Therapeutics Market share of key regional segments During Forecast Period.

The latest industry analysis and survey on Glaucoma Therapeutics provides sales outlook in 20+ countries, across key categories. Insights and outlook on Glaucoma Therapeutics market drivers, trends, and influencing factors are also included in the study.

Click Here To get a Sample Report (Including Full TOC, Table & Figures):-https://www.factmr.com/connectus/sample?flag=S&rep_id=4775

Key Segments Covered

Drug Class
- Prostaglandins
- Beta Blockers
- Alpha Agonists
- Carbonic Anhydrase Inhibitors
- Combination Medications
- Cholinergic Medications
End User
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers

Need More information about Report Methodology? Click here:-https://www.factmr.com/connectus/sample?flag=RM&rep_id=4775

Key Parameters analyzed while estimating the Glaucoma Therapeutics market include:

To analyze Drugs/ Therapeutic Area in Glaucoma Therapeutics :

Overall Population by age group/Prevalence or Incidence of any disease/Treatment Seeking Rate/Dosage pattern/Average duration of treatment/Overall treatment cost and Reimbursement are considered.

To analyze Consumables of Glaucoma Therapeutics:

Overall Population/Prevalence or Incidence of disease/treatment seeking rate/ average duration of the treatment/average number of devices used per patient / average number of procedure per device/ average selling price per device/reimbursement are considered.

To analyze Glaucoma Therapeutics Equipment:

Number of Healthcare facilities (Hospitals/Ambulatory Surgical Centers/Clinics etc.)

Average number of devices installed per facilities/ lifespan of the devices/replacement rate of the equipment/new sales of the equipment per year/average selling price per equipment are considered.

Moreover, it also gives meaningful as well as actionable insights on the competitive analysis of Glaucoma Therapeutics Market that are developing the current market scenario and which will be lucrative for the future demand of Glaucoma Therapeutics Market.

Crucial insights in Glaucoma Therapeutics market research report:

Underlying macro- and microeconomic factors impacting the Sales of Glaucoma Therapeutics market.
Basic overview of the Glaucoma Therapeutics, including market definition, classification, and applications.
Scrutinization of each market player based on mergers & acquisitions, R&D projects, and product launches.
Adoption trend and supply side analysis of Glaucoma Therapeutics across various industries.
Important regions and countries offering lucrative opportunities to market stakeholders.

The Demand of Glaucoma Therapeutics Market study includes the current market scenario on the global platform and also Sales of Glaucoma Therapeutics Market development during the forecast period.

To get all-in insights on the regional landscape of the Glaucoma Therapeutics Market, buy now:-https://www.factmr.com/checkout/4775

Competitive Landscape

Strategic collaborations enable manufacturers to increase production and meet consumer demand which will increase revenue and market share. New products and technologies will enable end-users to benefit from products that are eco-friendly by nature. Key developments in the market are as follows:

In May 2020, the U.S Food & Drug Administration approved Allergan Plc.’s DURYSTATM (bimatoprost implant) New Drug Application. The drug is amongst the first intracameral, sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma, or ocular hypertension
In October 2021, Novartis AG pledged to work with partners all around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care. The company has partnered with the International Agency for the Prevention of Blindness during the World Sight Day to initiate the #LoveYourEyes campaign

More Related Reports by Fact.MR on Healthcare Sector:

Sterile Compounding Pharmacies Market :-_ Sterile Compounding Pharmacies Market Growth to Spur with Rising Demand for Injectables during 2021-2031

Testosterone Nasal Gels Market:- Testosterone Nasal Gels Market Share Analysis By Indication, By Dosage (5mg, 10mg), By Distribution Channel & By Region Forecast, 2021-2031

Wireless Handheld Ultrasound Devices Market:- Small Size and Easy to Operate Functions to Boost the Sales of Wireless Handheld Ultrasound Devices during 2021-2031

The Market insights of Glaucoma Therapeutics will improve the revenue impact of businesses in various industries by:

Providing a framework tailored toward understanding the attractiveness quotient of various products/solutions/technologies in the Glaucoma Therapeutics Market
Guiding stakeholders to identify key problem areas pertaining to their consolidation strategies in the global Glaucoma Therapeutics market and offers solutions
Assessing the impact of changing regulatory dynamics in the regions in which companies are keen on expanding their footprints
Provides understanding of disruptive technology trends to help businesses make their transitions smoothly
Helping leading companies make strategy recalibrations ahead of their competitors and peers
Offers insights into promising synergies for top players aiming to retain their leadership position in the market & supply side analysis of Glaucoma Therapeutics market .

Browse More Reports by Fact.MR : –https://www.biospace.com/article/rising-demand-for-blood-thawing-systems-from-blood-banks-and-hospitals-augmenting-market-growth-fact-mr/

About Fact.MR:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Rising prevalence of glaucoma and other visual impairments have led to an increase in the demand for therapeutic drugs to treat these conditions. Around one-tenth of the elderly population suffers from glaucoma, which is expected to increase with each passing year. Consequently, the demand for better therapy options for the treatment of glaucoma is expected to boost demand for therapeutics.

On the back of these factors, the global glaucoma therapeutics market shall witness a gradual growth, at a CAGR of 2.9% during the forecast period (2020-2026). Other generic drivers, such as a greater geriatric population pool, a rise in the diabetic population and higher healthcare spending and infrastructure shall boost market growth.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4775

Key Takeaways of Global Glaucoma Therapeutics Market Study

Prostaglandins are anticipated to account for the maximum market share of the glaucoma therapeutics market. This is attributed to its increased adoption in first line glaucoma treatment. The drug reduces intraocular pressure (IOP) by increasing uveoscleral flow. Projections indicate a market share of more than two-fifth of the total glaucoma therapeutics market.
Combination medicines are becoming more prevalent for glaucoma treatment. Greater effectiveness of treatment over individual medications is a key growth driver for this segment. For example, the Rhopressa drug class, a combination formula developed by Aerie Pharmaceuticals, has been approved for usage in commercial glaucoma treatment. Projected CAGR for combination medicines is pegged at 4.7% during the forecast period.
Hospitals shall account for the majority of the share of glaucoma therapeutics between 2020 and 2026. Increasing number of patients coupled with the ability to provide optimum healthcare services are major growth drivers.
North America is set to remain a lucrative market for glaucoma therapeutics. Increased focus on research and development of therapeutic drugs and approvals of certain drug categories like Rhopressa are expected to leverage the region’s market share. Asia-Pacific is following close behind, with a projected CAGR of 3.2% during the forecast period. Introduction of new drugs like Travopost and Timolol are expected to invigorate Asia-Pacific’s market share.

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4775

COVID-19’s Impact:

Leading players are concentrating on safeguarding the supply chain of their products in response to the COVID-19 pandemic. Alcon, for instance, has initiated its Global Crisis Management program to ensure continuity of business operations. Manufacturing sites are functional to ensure production of essential glaucoma drugs. Bausch Health, another player, has directed its funds towards developing VIRAZOLE, a potential drug which may help fight the COVID-19 pandemic.

It is working in co-operation with key health authorities for the same. Aerie Pharmaceuticals reported a decline in the pace of volumes for its Rhopressa and Rocklatan drugs during the first quarter of 2020 due to COVID-19. Fortunately, no supply chain disruptions have been experienced. The company has adequate inventory to ensure a consistent supply for at least six months.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4775

“The glaucoma therapeutics market shows a positive growth trend. Its market is expected to be invigorated by continuous research and product development, especially in combination drugs. Leading market players have accordingly developed formulae which can assist in faster recovery of glaucoma patients,” concludes a Fact.MR analyst.

Combination Drugs; a Growth Lever for Market Players

The global glaucoma therapeutics market consists of the following market players: Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals, Inc. and Aerie Pharmaceuticals, Inc. Novartis AG’s Alcon division focuses on development of eye care products, such as Travatan, Simbrinza and Azarga. Allergan Plc., occupies the second position in the market, and include top selling brands like Lumigan, Alphagan, Ganfort and Combigan. More recently, the company also received an approval from the FDA to launch its DURYSTA^TMBiodegradable Sustained-Release Implant. This device is designed to reduce intraocular pressure in open-angle glaucoma or ocular hypertension patients.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Wound Tissue Analysis Solutions Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2189/wound-tissue-analysis-solutions-market

Wireless Neurostimulator Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2188/wireless-neurostimulator-market

Skin Cooling Systems Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2186/skin-cooling-systems-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com